|
|
Article: Other News To Note.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o Adventrx Pharmaceuticals Inc., of San Diego, presented results demonstrating synergistic HIV inhibitory activity of its broad spectrum antiviral drug candidate, ANX-201, when combined with approved nucleoside and nucleotide reverse transcriptase inhibitors (N(t)RTI) in preclinical tests. The results were presented at the 4th Annual International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Sydney, Australia. The preclinical results suggested that ANX-201 and commonly prescribed N(t)RTIs represent a promising combination in multidrug antiretroviral therapy, the company said.
o Affymetrix Inc., of Santa Clara, Calif., and Partners ...
Related newspaper, magazine, and journal articles:
|
|
Article: Depomed's Proquin XR Wins FDA Approval As Treatment ...
BIOWORLD Today;
November 3, 2009 ;
700+ words
... ... percent on news that the FDA approved Proquin XR, a once-daily, extended-release ... uncomplicated urinary tract infections (UTIs), Proquin XR's efficacy is being touted by Depomed ... trial of 1,037 patients showed that Proquin XR eradicated 93.4 percent of the bacteria ...
|
|